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doi:10.1016/j.jfma.2011.03.005Background/Purpose: Between 10% and 20% of cancer pain patients fail to obtain adequate
pain relief despite comprehensive medical management. The totally implantable program-
mable intrathecal drug delivery system (IDDS) is an attractive option for managing refractory
cancer pain. In suitable patients, IDDS can provide reliable long-term analgesia without any
permanent nerve or plexus destruction. IDDS can also allow patient care on an outpatient
basis. In Taiwan, however, the experience of using IDDS in terminally ill cancer patients is very
limited.
Methods: This retrospective study, describes experience of managing totally implantable
programmable IDDS in 6 refractory cancer pain patients including patient selection, intraspinal
morphine trial, surgical techniques, complications, and drug adjustment. Pain scores and func-
tional status were compared before and after IDDS.
Results: By delivering liberal dose of intrathecal morphine, patients’ pain scores decreased from
10 to 3.5. Due to much better pain control and improved quality of life, Eastern Cooperative
Oncology Group performance status also improved in 4/6 patients. During the mean 5  4.1
months of follow-up, two patients experienced pocket seroma, and resolved spontaneously after
short-term abdominal binder compression. Otherwise, no serious complication was noted.
Conclusion: Intrathecal morphine delivery by using totally implantable programmable IDDS is an
effective method to relieve refractory cancer pain.
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254 C.-P. Lin et al.Introduction who achieved >50% pain reduction were considered eligibleTen to 20 percent of cancer pain cannot be alleviated with
the World Health Organization three-step pain relief
ladder.1 A multi-center survey of cancer pain among
Taiwanese oncology outpatients clinics showed that 54% of
patients suffered from pain and 35% of these patients rated
their pain as severe. Among those analgesic-treated
patients, 35.6% were dissatisfied by their pain manage-
ment and 6.7 % felt no improvement at all.2 For these
refractory cancer pain patients, intraspinal opioids can be
the fourth step after sequential escalation of systemic
medication.3
The indication andeffectiveness of intraspinal techniques
for cancer pain is widely accepted.4 In 2002, Smith et al5
conducted a randomized multicenter clinical trial investi-
gating the safety and efficacy of an intrathecal drug delivery
system (IDDS) plus comprehensive medical management
(CMM) versus CMM alone in patients with refractory cancer
pain. Patients receiving IDDS plus CMM had significant
improvement in pain control, reduction in common drug
toxicities and improved survival compared with patients
receiving CMM alone. According to current consensuses,4,6
IDDS can be a good alternative for selected cancer pain
patients, such as those with refractory cancer pain that
cannot be relieved by conventional routes or suffered from
intolerable side effects. However, the experience of using
IDDS to manage refractory cancer pain is very limited in
Taiwan. This is a preliminary report of single tertiarymedical
center experience on IDDS, with detailed patient selection,
intraspinal morphine trial, surgical techniques, complica-
tions and drug adjustment strategies for 6 consecutive
patients.
Materials and methods
Patient selection and intraspinal morphine trial
Refractory cancer pain is defined as failure to achieve
adequate analgesia despite maximal opioids escalation and
rotation, and development of analgesic-related toxicity or
intolerant to opioid side effects. We followed the protocol
for refractory cancer pain management at National Taiwan
University Hospital (Fig. 1). Patients suffering from wide-
spread pain or failed to respond to neuroablative procedures
were indicated for intraspinal (epidural or intrathecal)
morphine therapy. These patients were considered eligible
for permanent IDDS implantation if their life expectancy was
>3 months. We excluded patients with bleeding tendency,
active infection, and brain metastasis.
Before permanent IDDS implantation, all patients were
admitted to hospital and initiated an intraspinal morphine
trial for 7 days. The intraspinal morphine can be delivered
by daily intrathecal injection, continuous epidural infusion
or continuous intrathecal infusion. The relative potency for
intravenous:epidural:intrathecal morphine is 1:10:100. It is
well known that under equipotent dose, the opioid-related
side effects, especially nausea/vomiting and constipation,
are markedly decreased when delivered more centrally.6
The intraspinal morphine dosage was adjusted according
to each patient’s pain intensity and side effects. Patientsfor permanent IDDS implantation.
Implantation techniques for permanent IDDS
Applied standardized surgical procedure was followed for
every patient. After induction of general anesthesia, the
patient was put in lateral decubitus position on the operating
table with the pre-planed side of implantation upward.
Intraoperative fluoroscopy was mandatory to confirm access
to the L3-4 intrathecal space and the catheter tip to the
optimal position according to patient disease status. Intra-
thecal catheterization was performed by paramedian
approach with gentle oblique angle (Fig. 2A) to optimize
cerebrospinal fluid flow and decrease the risk of catheter
kink or fracture. The catheter was then fixed on dorsal
lumbar fascia with a special anchorage device (Fig. 2B) to
accommodate possible vigorous movement after patient’s
general condition improved. The intrathecal catheter was
then tunneled to the lower abdomen subcutaneous pocket
where the programmable pump was implanted.
Patients follow up after IDDS implantation
After the operation, IDDS was set according to the intra-
spinal morphine trial result. Extra dose of analgesics might
be necessary for acute postoperative wound pain. Patients
were discharged 7 to 10 days after healing of surgical
wounds and stabilization of intrathecal morphine dose.
Patients then continued their previous treatment plan of
either systemic chemotherapy or supportive care, and were
hospitalized whenever clinically indicated.
Each patient’s pain severity was measured by numeric
rating scale from 0 to 10. Pain scores and equipotent
morphine dosages were recorded at every visit and further
analyzed at the following time points: before pain specialist
consultation; screen for eligibility of IDDS (before intra-
spinal morphine trial); after stable dose of intraspinal
morphine trial; 14 days after IDDS implantation; and optimal
condition during regular follow-up. The patient’s functional
status was recorded using the Eastern Cooperative Oncology
Group (ECOG) performance status before and 14 days after
implantation.7
Statistical analysis
Pain scores at different time points were expressed by
median (range). Pain score were compared between the
different time points by repeated measures analysis of
variance and multiple means Waller-Duncan ratios methods.
ECOG status was compared using the nonparametric Wil-
coxon matched-pair signed-rank test. A p value <0.05 was
considered statistically significant.
Results
From January 2007 to January 2010, 6 refractory cancer
pain patients received IDDS. The characteristics of these
patients are summarized in Table 1. Four patients had
inadequate pain control despite maximal drug escalation
Figure 1 Decision-making flow chart for refractory cancer pain management.
IDDS for refractory cancer pain patients 255and rotation and two were intolerant to the adverse effects
of opioids with intractable nausea and vomiting.
The intraspinal morphine trial procedures were not
consistent in our study population. For the first case, daily
lumbar puncture by 27 gauge spinal needle was attempted
to deliver intrathecal morphine. This procedure had some
drawbacks: the patient needed repeated transfer to oper-
ation room for consecutive 7 days; and the analgesic effect
was not stable and the duration of the single shot intra-
thecal morphine lasted only for 18 to 22 hours e the patient
suffered from intractable pain during the drug windows.
Thereafter, a continuous epidural morphine infusion
program was adopted before implanting IDDS. The epiduralFigure 2 Intraoperative images. (A) Check the spinal level, guid
(B) Fixate the intrathecal catheter with special anchorage devicecatheter was inserted in the operation room under fluo-
roscopy guide. After confirming proper catheter position
and fixation, dosage adjustment could be easily managed in
the ward. Since the intrathecal space is an immune-
privileged site and infection was always a concern espe-
cially in cancer patients, great care was taken with the
externalized catheter. Only one patient was shifted to
a temporary intrathecal catheter to provide adequate
analgesia. His initial intrathecal dose was too high for the
epidural route to be effective.
The patients’ pain scores were 10 (9e10) at pain
specialist consultation, 9 (8e10) after medication adjust-
ment including opioids and adjuvant agents. After thee the catheter entry and tip final position under fluoroscopy.
on dorsal lumbar fascia.
Table 1 Patient demographics.
Gender/age Primary cancer diagnosis Major pain character ECOG before IDDS ECOG after IDDS
Patient 1 M/58 Hepatocellular carcinoma Somatic 3 3
Patient 2 M/56 Rectal cancer Visceral 3 3
Patient 3 M/58 Rectal cancer Neuropathic 3 2
Patient 4 F/25 Buttock synovial sarcoma Neuropathic 3 1
Patient 5 F/70 Cholangiocarcinoma Somatic 4 3
Patient 6 M/48 Sigmoid colon cancer Visceral 3 2
ECOG: Eastern Cooperative Oncology Group performance status: 0 Z fully active and 4 Z completely disabled.
256 C.-P. Lin et al.intraspinal morphine trial, the pain scores decreased to 3.5
(2e4), which was a statistically significant change
(p < 0.01). The two patients who suffered from severe
nausea and vomiting related to opioids could tolerate the
intraspinal morphine trial well and easily escalated dose to
adequate analgesia. All six patients were satisfied with the
analgesic efficacy and received IDDS according to trial
result, the pain score was stable from the immediate
postimplantation period to follow-up visits (Fig. 3). The
course of equipotent morphine dosage escalation is illus-
trated in Fig. 4. Two patients suffered from pocket seroma
and one patient also had back wound seroma. During mean
5  4.1 months follow-up, no other complication was noted
such as central nervous system infection, nerve roots or
spinal cord injury. Four patients had functional improve-
ment at 14 days after IDDS implantation, while the other
two remained unchanged (Table 1). All six patients felt
significant improvement of their quality of life with better
pain control.
Discussion
Our results in these six refractory cancer pain patients
showed that IDDS improved pain control, performanceFigure 3 Pain scores at different time points. The evolutional
change of pain scores at five time points including pain specialist
consultation (Consult), before intraspinal morphine trial (Pre-
IDDS), during intraspinal morphine trial (Trial), 14 days after
IDDS implantation (Post-IDDS) and maintenance phase (Main-
tain); pain scores are presented by median and range.status and quality of life. The pain scores significantly
decreased from 10 to 3.5, although concomitantly daily
intravenous morphine equivalent dose was rapidly increased
under intrathecal drug administration. During the intra-
spinal morphine trial period, the equipotent morphine dose
nearly doubled from the opioid dosage before the trial. With
IDDS, morphine can be delivered directly to receptors in
spinal cord dorsal horn and brain. This improves efficacy and
reduces common side effects such as nausea/vomiting and
especially constipation.6 Functional status improved in four
of our patients after better pain control. Prolonged refrac-
tory pain status could lead to physical exhaustion and
functional decline. Therefore, early intervention is essential
to improve performance status among cancer patients. We
cannot generalize the results of this study to patients with
refractory pain due to the small sample size.
IDDS-related complications have been reported8 and up to
1% IDDS are related to central nervous system infections that
necessitate pump and catheter removal. Minor complications
such as local seroma around pump pocket site are not
uncommon. In our experience, no surgical related infection
or acute complication was noted. However, two patients
suffered from postoperative pocket seroma; one of them
combined with back wound seroma. One of the possible
causes is the low serum albumin level,9 as observed in our
patients (33 g/l and 31g/l respectively). Further studies are
needed on the efficacy of albumin supplements prior to the
procedure for reducing seroma. The back wound seroma
might also be secondary to persistent cerebrospinal fluid
(CSF) leakage.10 This is less likely in our study because our
patients did not show any other symptoms related to
persistent CSF leakage such as positional headache. InFigure 4 Analgesic dosage adjustment before and after IDDS.
IDDS for refractory cancer pain patients 257addition, their seroma resolved spontaneously after short-
term use of abdominal binder compression. Another
complication with IDDS implantation is epidural or intra-
thecal bleeding/hematoma accumulation which is sus-
pected if patients complain of rapid increase of focal back
pain associated with a progressive neurologic deficit.10
Magnetic resource imaging (MRI) is necessary to confirm
the diagnosis. None of the patients suffered from similar
symptoms. However, one patient had to undergo regular
MRI examinations for monitoring of his cancer status. The
IDDS pump will shut down when exposed to a magnetic field
> 1.5 Tesla, and resume its preprogrammed setting after
leaving the magnetic field. After MRI examination, IDDS
worked well and MR image quality was affected only at the
pump area.
Morphine remains the gold standard for spinal adminis-
tered analgesia and the only opioid approved by the FDA for
intrathecal delivery. In this study, two patients required
a very high dose of morphine daily for adequate pain control:
16 mg and 21 mg intrathecal morphine (equivalent to
1600 mg and 2100 mg intravenously), respectively. However,
delivering a high concentration (>25 mg/ml), high daily dose
(>10 mg/day) of morphine intrathecally may increase risk
of intrathecal granuloma formation.11 According to recent
guidelines from the 2007 Polyanalgesic Consensus Confer-
ence,12 morphine may be shifted to other first-line medica-
tion (including hydromorphone and ziconotide) or second-
line medication. Unfortunately, these drugs are not avail-
able in Taiwan.
Morphine delivered by IDDS can be adjusted easily
at both outpatient clinic and inpatient setting by hand-
held programmer. Dosage titration is guided according to
patient’s pain level and site of care as morphine adjustment
of hospitalized patients can be managed more aggressively.
Generally, if pain score is 5 to 6, the dose can be increased
by 25% to 50% daily. If pain score is 7 to 10, 50% to 100% dose
escalation might be mandatory and patient should be
closely monitored for possible drug toxicities in the initial 12
to 24 hours. As cancer progresses, the patient’s morphine-
equivalent daily dosage is tailored to reach adequate pain
control without hesitation. In our practice, IDDS pump
drug refill is arranged in an ambulatory surgery setting for
complete sterile environment. Each refill lasts from 2 weeks
to 3 months depending on the daily dose requirement.
This is a preliminary report on the effect of intrathecal
morphine delivery on patients with refractory cancer pain.
Although this study has a small sample size, it supports
the use of intrathecal morphine delivery with totallyimplantable programmable pumps to ameliorate cancer
pain. Further evaluation is necessary to validate the effi-
cacy of intrathecal morphine delivery, but it can be an
alternative for cancer patients with refractory pain.References
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